| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
|
5,334 |
5,100 |
$464K |
| 99213 |
|
2,590 |
2,475 |
$158K |
| 99204 |
|
849 |
848 |
$94K |
| 64493 |
|
211 |
199 |
$31K |
| 64635 |
|
99 |
89 |
$18K |
| 64494 |
|
210 |
198 |
$14K |
| 64495 |
|
183 |
174 |
$14K |
| 62323 |
|
108 |
108 |
$11K |
| 64636 |
|
100 |
87 |
$8K |
| 20611 |
|
106 |
83 |
$7K |
| 99152 |
|
371 |
361 |
$5K |
| 76942 |
|
92 |
87 |
$4K |
| 96372 |
|
311 |
298 |
$4K |
| J3301 |
Injection, triamcinolone acetonide, not otherwise specified, 10 mg |
618 |
570 |
$3K |
| 64490 |
|
15 |
14 |
$911.33 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
174 |
164 |
$541.73 |
| 64491 |
|
15 |
14 |
$443.46 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
172 |
167 |
$299.79 |
| J7030 |
Infusion, normal saline solution , 1000 cc |
53 |
53 |
$232.08 |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
58 |
58 |
$4.40 |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
13 |
13 |
$3.48 |
| G8431 |
Screening for depression is documented as being positive and a follow-up plan is documented |
33 |
33 |
$0.00 |
| G9903 |
Patient screened for tobacco use and identified as a tobacco non-user |
86 |
86 |
$0.00 |
| G9906 |
Patient identified as a tobacco user received tobacco cessation intervention during the measurement period or in the six months prior to the measurement period (counseling and/or pharmacotherapy) |
13 |
13 |
$0.00 |
| G9902 |
Patient screened for tobacco use and identified as a tobacco user |
13 |
13 |
$0.00 |
| G2197 |
Patient screened for unhealthy alcohol use using a systematic screening method and not identified as an unhealthy alcohol user |
106 |
106 |
$0.00 |
| G8510 |
Screening for depression is documented as negative, a follow-up plan is not required |
33 |
33 |
$0.00 |